Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31574502 | 1.00 | GABRA1 (0.61) | GABRA1GABRB2MAPTKMT2AMEN1 | |
| 3,4-Methylendioxy Acetophenone SCHEMBL137979 | 0.85 | KDM4E (0.71) | MAPTKMT2AMEN1ALDH1A1MAPK1 | |
| 3,4-Methylendioxy Acetophenone SCHEMBL29405437 | 0.85 | KDM4E (0.71) | MAPTKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL2945422 | 0.84 | ALDH1A1 (0.73) | GABRA1GABRB2MAPTKMT2AMEN1 | |
| SCHEMBL5899521 | 0.83 | CHEK2 (0.67) | GABRA1GABRB2MAPTALDH1A1MAPK1 | |
| SCHEMBL22221008 | 0.82 | GABRA1 (0.68) | GABRA1GABRB2KMT2AMEN1ALDH1A1 | |
| SCHEMBL5943881 | 0.80 | HDAC6 (0.61) | GABRA1GABRB2MAPTKMT2AMEN1 | |
| SCHEMBL5899759 | 0.79 | MAPT (0.68) | MAPTKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL2995600 | 0.79 | MAPT (0.67) | GABRA1GABRB2MAPTKMT2AMEN1 | |
| SCHEMBL5377159 | 0.76 | CYP3A4 (0.69) | GABRA1GABRB2MAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186900-A1 | COMPOUND | STERIX LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| EP-2013176-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | Sterix Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096647-A2 | DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER | STERIX LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-6939985-B1 | covalently coupling organic compounds by reacting an aromatic ring compound having a halogen or halogen-like substituent at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a base | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2005-09-06 | — | — | US | disclosed |
| US-6559310-B2 | Reacting a halogen aromatic derivative at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-05-06 | — | — | US | disclosed |
| US-20020193604-A1 | Aryl borates | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-12-19 | — | — | US | disclosed |
| US-6399779-B1 | REACTING A HALOGEN AROMATIC DERIVATIVE AT A COUPLING POSITION WITH A DIBORON DERIVATIVE IN THE PRESENCE OF A GROUP 8 METAL CATALYST | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-06-04 | — | — | US | disclosed |
| US-20020032339-A1 | ARYL BORATES | BORON MOLECULAR LIMITED (AU) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193604-A1 | Aryl borates | BRD4, ABL1, BRD3 | GABRA1 743/4885GABRB2 620/4885MAPT 4324/4885 |
| US-20090186900-A1 | COMPOUND | HSD17B2, HSD17B11, CYP17A1 | GABRA1 1793/4885GABRB2 1194/4885MAPT 929/4885 |
| US-20020032339-A1 | ARYL BORATES | TBCB, HAT1, UBE2B | GABRA1 631/4885GABRB2 246/4885MAPT 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.